Matthew L. Fero

Appointments and Affiliations

Fred Hutchinson Cancer Research Center
Clinical Research Division
Associate Member, Appointed 2000
University of Washington
School of medicine
Oncology
Associate Professor, Appointed: 2000
Professional Headshot of Matthew Fero

Mailing Address

Fred Hutchinson Cancer Research Center
D4-100
P.O. Box 19024
Seattle, Washington 98109-1024
United States

Contact

Phone: (206) 667-5065
Fax: (206) 667-1494
mfero@fhcrc.org
http://labs.fhcrc.org/fero/

Degrees

M.D., University of California, Irvine, 1990.
B.A., University of California, Berkeley, Microbiology, 1984.

Research Interests

The additional layers of regulation and functional redundancy of cell cycle proteins in mammals may reflect the need for alternative, tissue specific, growth control pathways. Mouse models have challanged our understanding the biochemical mechanisms of CDK regulation in mammals and have demonstrated both generalized and tissue specific patterns of cellular growth control. Targeted disruption of the CKI genes, p27Kip1, causes a hyperplastic syndrome with increased tumor susceptibility, and CDK activation.

A non-protein encoding RNA transcript, Xpcl1, is located on the X-chromosome and encodes a cluster of microRNAs. When activated these miRNA cause T-cell lymphomas through an unknown mechanism. We have shown that Xpcl1 expression and cell cycle activation are highly synergistic with respect to tumor development. We are working to understand the mechanism of action of the Xpcl1 miRNA and whether they may be used as novel diagnostic or therapeutic targets.

Although hematopoiesis is one of the best characterized cellular developmental pathways our understanding key regulators is lacking as evidenced by our limited ability to faithfully grow blood cells in the laboratory and our inability to purify homogeneous progenitor populations. We have initiated a project to address these constraints by characterizing transcriptiome variation of individual hematopoietic progenitor populations with second generation RNA-Seq technology, and the development of novel gene expression reporters.

Future Research

The Fero lab is highly interactive and has collaborative interactions with local and international groups. Our current research projects include the following:
  • Mechanism of tumor suppression by the p27Kip1 CDK inhibitor
  • Role of the Xpcl1 microRNA cluster in T-cell development
  • Single cell transcriptome heterogeneity in hematopoiesis
  • Novel gene mutations in leukemia and lymphoma

Previous Positions

1998-2000: Acting Assistant Professor, Oncology Division, Department of Medicine, University of Washington Medical Center
1996-1999: Associate in Clinical Research, Clinical Division, Fred Hutchinson Cancer Research Center
1994-1998: Acting Instructor, Department of Medicine, University of Washington Medical Center
1993-1996: Oncology Fellowship, University of Washington Medical Center
1990-1993: Internal Medicine Residency, Mayo Graduate School of Medicine

Additional Experience

Clinical Expertise: Hematopoietic stem cell transplantation

Memberships

American Association for Cancer Research
American Society of Hematology
Puget Sound Oncology Consortium

Honors and Awards

2009: Fellow, American College of Physicians
1997: Fellowship, Friends of Jose Carreras International Leukemia Foundation
1996: Mentored Clinical Scientist Training Award (K-08), National Cancer Institute
1986: May Spurgeon Honor Scholarship, University of California, Irvine, College of Medicine
1984: Honor Student Society. University of California Berkeley
1982: Alumni Scholar, University of California Berkeley

Board Certification and Eligibility

1991: Diplomate, National Board of Medical Examiners
1993-2003: Diplomate in Internal Medicine, American Board of Internal Medicine
1996-2007: Diplomate in Medical Oncology, American Board of Internal Medicine

Current License(s) to Practice

1993-present: Washington State Medical License

Patents

Compositions and methods for mediating cell cycle progression, Patent Number: 5958769, 1999, Institution-owned, United States.

Funding

  • NIH/NHLBI: Controlling Hematopoietic Lineage Commitment from ESC to platelets, Co-Investigator (P.I.: Torok-Storb, B.), 9/30/2009 - 8/31/2016.
  • NIH/NIDDK: Core Center of Excellence in Hematology, Sub-Project: Core E, Project Leader (P.I.: Torok-Storb, B.), 9/30/2010-06/30/2015.

Recent Publications

2013
2012
2011
2009
2008
2007
2006
2005
2004
2002